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Swine plasma immunoglobulins for prevention and treatment 
of post-weaning diarrhoea:  Safety and Preliminary results  
Background 
Aim 
Figure 3: ppIgG in vivo (model of PWD) 
Conclusions 
Post-weaning diarrhoea (PWD) is a common condition in intensive swine 
production, resulting in reduced welfare of weaners, high consumption of 
antibiotics and zinc oxide, and economic losses for the farmer as a result of pig 
disease and death, and associated treatment costs. 
 To develop an antibiotic alternative, based on natural antibodies 
(immunoglobulins) derived directly from inexpensive raw material 
(swine blood plasma) for oral provision, and protection against PWD. 
Figure 2: ppIgG reacts with relevant bacteria in vitro 
Figure 1: Purified porcine IgG (ppIgG) 
A: Indirect (whole cell ELISA) 
Figure 2: ppIgG reacts with relevant bacteria in vitro 
Three different in vitro assays were applied (see below) and it was observed that ppIgG 
could selective bind to relevant pig-pathogenic bacteria. 
Indirect: ppIgG was added in 2-fold dilution series from 10 to 0.02 mg/ml. After 1 hour of 
incubation and 3 washes in PBS-Tween, detection antibody (HRP-conjugated rabbit anti- 
porcine Ig (DAKO)) was added and detected ppIgG bound to relevant bacteria (i.e. ETEC 
and S. enterica) but not to the fish-pathogen Y. ruckeri. 
Competitive ELISA: Along with ppIgG either Genway Biotech’s anti-E. coli (18-511-
245057) or anti-salmonella (18-511-245055) HRP-conjugated antibodies were used. The 
read out was dependent on the ability of the ppIgG to inhibit the signal by interfering with 
the binding of conjugated antibody to its ligands. Denaturing ppIgG (60-70°C) significantly 
reduced the ability of the ppIgG to inhibit the binding of the detection antibody to the 
bacterial antigens. 
Adhesion-inhibition assay: Fluorescently stained bacteria were pre-incubated at 4°C with 
various amounts of ppIgG (from 100 mg/ml to 0.2 mg/ml, plus controls with no ppIgG) 
before added to 15.000 neonatal porcine jejunum derived IPEC-J2 cells/well (DSMZ, 
Braunschweig, Germany) for additional 3 hrs of incubation at 4°C. After adhesion, plates 
were washed thrice and buffer was added before reading fluorescence at 485/528 nm by 
means of Synergy HT (BioTek) using Gen5 software (BioTek). ppIgG inhibits the binding of 
the four pig-relevant bacteria to IPEC-J2 cells. 
Figure 1: Pig plasma IgG (ppIgG) was purified from blood 
plasma at UpFront Chromatography A/S (Copenhagen) by high-
volume Expanded Bed Adsorption with a proprietary adsorbent. 
Plasma was obtained from a DAKA A/S (Lunderskov, Denmark). 
ppIgG (1 mg/ml) was run under reducing conditions on 12% SDS 
PAGE. In parallel, Western blotting (WB) was performed on the 
same sample. The blot was developed with biotinylated rabbit 
anti-pig IgG F(ab)2 antibody, followed by alkaline phosphatase-
coupled streptavidin. 
By SDS PAGE and Western blotting analysis the ppIgG was 
estimated to consist of approximately 85% pure immunoglobulin. 
C: Inhibition of ETEC adhesion 
• Purified porcine immunoglobulin (ppIgG) binds PWD-inducing 
Enterotoxigenic Escherichia coli (ETEC), and inhibits ETEC adhesion 
to  porcine intestinal epithelial cells in vitro. 
• Experimental ETEC infection was cleared significantly faster in 
weaner piglets given a ppIgG feed supplement. 
• Based on next-generation sequencing data, ppIgG inhibits ileal 
adhesion of bacteria from the family Enterobacteriaceae.  
• No adverse side effects were observed by using ppIgG as a feed 
supplement. 
• These results suggest that ppIgG could be used for treatment of 
PWD and reduce antibiotic consumption. 
B: Competitive ELISA 
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A: Experiment plan 
B: Shedding of ETEC C: Enterobacteriaceae in ileum 
= ppIgG = HRP:anti-Pig IgG 
 antibody 
= ppIgG = HRP:anti-E. coli /        
   Salmonella antibody 
= Bacterial lysate 
= Fluorescent bacteria = ppIgG 
Figure 3: ppIgG reduces ETEC infection in PWD model 
A: Offspring of 11 sows were randomly mixed after farrowing (day -28), to avoid 
confounding treatment effect with the genetic background. At 28 days of age, 24 piglets 
were randomly selected, weaned and distributed according to their experimental group 
(day 0). On day 1 two groups (Infected+ppIgG and Infected) were given 2x1010 CFU of 
ETEC (E. coli F4+O149). The group ‘Infected+ppIgG was provided every day with 
oat/wheat-feed mixed with 160 ml (32 grams) of ppIgG. After 12 days the weaner piglets 
were killed and inspected. B: Faecal samples were collected on day 1, 3, 5, 7, 9 and 11 
post infection and analysed by F4-specific qPCR for shedding of the ETEC. The infection was 
cleared significantly faster in the ‘infection+ppIgG’ group compared to the infection control 
group (p=0.0007), even though onset of infection was faster in infection+ppIgG than in the 
infection control group (p=0.0017). C: DNA was purified from the ileum samples (taken at  
autopsy). V1-V2 regions of 16S rRNA gene was amplified, and amplicons were sequenced 
on MiSeq platform (Illumina Inc. San Diego, USA). The resulting read counts were then 
analysed on the family level, which showed a significantly lowered (p<0.001) colonisation 
by the family Enterobacteriaceae in the ileum as compared to both the non-infected control 
and the infected control group. Collectively the data presented in Figure 2+3 suggest 
that ppIgG inhibits ileal/intestinal adhesion of bacteria from this family.  
All animal procedures were approved by the Danish Animal Experiments Inspectorate under the Ministry of Justice (permit number: 2014-15-2934-01048) and animal experiments were conducted in strict accordance with their guidelines. 
